Evidence map›Paper›PMID 42016756›Full record

ArticleExploration (Beijing, China)2026

Modification-Response Integrated Modules Driven Cyclization-Dependent Prodrug Self-Assembly for Reshaping Pro-Apoptotic Tumor Redox Homeostasis.

Yixin Sun, Shiyi Zuo, Wenfeng Zang, Lingxiao Li, Xianbao Shi, Mingzhong Li, Zhonggui He, Bingjun Sun, Jin Sun

Abstract read
In one paragraph

Article in Exploration (Beijing, China), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yixin SunDepartment of Pharmaceutics Wuya College of Innovation Shenyang Pharmaceutical University Shenyang China.
Shiyi ZuoDepartment of Pharmaceutics Wuya College of Innovation Shenyang Pharmaceutical University Shenyang China.
Wenfeng ZangDepartment of Pharmaceutics Wuya College of Innovation Shenyang Pharmaceutical University Shenyang China.
Lingxiao LiDepartment of Pharmaceutics Wuya College of Innovation Shenyang Pharmaceutical University Shenyang China.
Xianbao ShiDepartment of Pharmacy The First Affiliated Hospital of Jinzhou Medical University Jinzhou China.
Mingzhong LiLeicester School of Pharmacy De Montfort University Leicester UK.
Zhonggui HeDepartment of Pharmaceutics Wuya College of Innovation Shenyang Pharmaceutical University Shenyang China.
Bingjun SunDepartment of Pharmaceutics Wuya College of Innovation Shenyang Pharmaceutical University Shenyang China.ORCID https://orcid.org/0000-0001-7986-5434
Jin SunDepartment of Pharmaceutics Wuya College of Innovation Shenyang Pharmaceutical University Shenyang China.ORCID https://orcid.org/0000-0001-5470-1599

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Affected by the complexity and heterogeneity of the tumor redox microenvironment, chemotherapy often fails to achieve satisfactory clinical outcomes. Modular design of prodrug nanoassemblies presents tremendous potential in upgrading the therapeutic index of chemotherapeutic agents. Given the biochemical vulnerability of tumor redox homeostasis, we fabricated five-membered cyclic chalcogenide-linked paclitaxel prodrug nanoassemblies, which realized tumor site-specific activation and reshaped the pro-apoptotic tumor redox homeostasis. Cyclic diselenide and cyclic disulfide bonds integrated the modification modules and response modules to minimize the utilization of non-pharmacodynamic moieties and increase druggability. Importantly, the modification-response integrated modules could simultaneously block the glutathione-glutathione peroxidase (GSH/GPx) antioxidant system and amplify reactive oxygen species (ROS) generation. The reshaping of the tumor redox homeostasis cascade triggered the loss of mitochondrial membrane potential and apoptosis of tumor cells, which synergistically potentiated the antitumor effects of paclitaxel. Such an intelligent prodrug nanoplatform brought new perspectives for constructing advanced antitumor nanomedicines with significant clinical research value.

Indexed as

cancer therapycyclic chalcogenidesmodification‐response integrated modulesprodrug nanoassembliestumor redox homeostasis

Identifiers

PMID42016756
PMCPMC13094520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.